Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade

Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade

Adoptive cell therapy (ACT), based on treatment with autologous tumor infiltrating lymphocyte (TIL)-derived or genetically modified chimeric antigen receptor (CAR) T cells, has become a potentially curative therapy for subgroups of patients with melanoma and hematological malignancies. To further im...

Full description

Bibliographic Details
Main Authors: Mie Linder Hübbe, Ditte Elisabeth Jæhger, Thomas Lars Andresen, Mads Hald Andersen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Immunology
Subjects:
cancer immunotherapy
immune checkpoint blockade
combination therapies
T-cell therapy
dendritic cells
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.578349/full

Similar Items

Similar Items